Karolinska Institutet Holding

What Karolinska Institutet Holding does

Karolinska Institutet Holding, operating commercially as KI Innovation (formerly Karolinska Institutet Innovation), is a privately held Swedish Aktiebolag incorporated in 1995 and headquartered in Solna, Sweden. The entity functions as the innovation and commercialization arm associated with Karolinska Institutet, one of the world's leading medical universities. It operates a four-stage life science innovation ecosystem: the Innovation Lab for early-stage researchers to assess feasibility and shape ideas; KI Science Park as a community platform connecting startups, industry, and academia; the KI Incubator providing business development, coaching, and resources for scaling startups; and an Access to Capital service offering co-investment and capital introduction for portfolio companies.

The company's underlying business model combines professional services (advisory, coaching, community programming) with capital participation in portfolio companies. Customer segments are researchers exploring commercialization, life science startups requiring scaling support, and industry partners seeking collaboration access. Revenue is not publicly disclosed and headcount is reported at 1-10, consistent with a lean holding/innovation operator rather than a services firm with scale delivery teams.

Notable portfolio outcomes include AstmaTuner (wireless lung function monitoring), HeartRunner (cardiac arrest alert system), Collective Minds Radiology (an AI-supported platform connecting more than 8,000 radiologists globally), and Stratipath (clinically validated AI-based pathology software). In April 2026, the organization rebranded to KI Innovation and secured visibility through the AbbVie Scandinavia Golden Ticket awarded to incubator company Serendo Therapeutics. Technology and AI capability reside primarily within portfolio companies rather than at the holding-entity level.

Name

Karolinska Institutet Holding

Legal name

KI Innovations AB

Website

https://kiholding.se

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

1–10 employees

Short description

KI Innovation is the life science innovation and commercialization arm of Karolinska Institutet, operating Innovation Lab, KI Science Park, KI Incubator, and Access to Capital services to help Swedish researchers and startups develop, scale, and fund healthcare ventures.

Ownership category

akta.pro rank

Product category

Life Science Innovation Services

NAICS

Management, Scientific, and Technical Consulting Services (5416), Portfolio Management and Investment Advice (523940), Professional, Scientific, and Technical Services (54), All Other Professional, Scientific, and Technical Services (541990)

SIC

Services-Management Consulting Services (8742), Investment Advice (6282), Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Technology Transfer & Innovation-Driven Research Universities (High Commercialization) (EDAHABAH)

Keywords

• Life science innovation
• Research commercialization
• Startup incubation
• Science park services
• Biotech venture support

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Innovation Support Services: Provides business development, coaching, and resources to transform research into commercial products and services within life science.
2. Access to Capital: KI Innovation offers co-investment opportunities and access to capital for companies, suggesting investment/equity-based revenue from successful portfolio companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Karolinska Institutet Holding, operating through its subsidiary KI Innovation (formerly Karolinska Institutet Innovation), provides innovation support and commercialization services for life science research. It connects academic researchers, startups, and industry partners through four core programs: Innovation Lab (early-stage feasibility), KI Science Park (community), KI Incubator (business development), and Access to Capital (investment support).

Product overview

KI Innovation is an innovation support organization associated with Karolinska Institutet that operates a unified ecosystem with multiple entry points for life science innovation. The portfolio consists of four interconnected core services: Innovation Lab (for early-stage researchers to assess feasibility and shape ideas), KI Science Park (a community platform connecting startups, industry and academia), KI Incubator (business development and coaching for scaling startups), and Access to Capital (investment and co-investment services). Together, these services support the full innovation journey from early research ideas to global companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Innovation Lab Early-stage program for researchers to explore the commercial feasibility of life science discoveries, including concept validation and market assessment.
• KI Science Park Community-based platform connecting life science startups, researchers, and industry partners in a collaborative environment in Stockholm/Solna, Sweden.
• KI Incubator Business development program providing structured support, mentorship, and resources to help life science startups grow from concept to commercialization.
• Access to Capital Investment and co-investment services helping life science ventures secure funding through direct investment, syndication, and investor network connections.

Quantifiable outcome

• 8,000+ radiologists connected through portfolio company Collective Minds Radiology

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Partnerships

One partnership is on record.

• AbbVie ScandinaviacoreStrategic or Co-development Partner · 24 April 2026Serendo Therapeutics AB, a KI Incubator company, was awarded the AbbVie Scandinavia Golden Ticket 2026, providing recognition and support for innovative biotech startups emerging from Karolinska Institutet's innovation ecosystem.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Oxford University Innovation: Tech transfer and innovation arm of the University of Oxford. Closest direct comparable to KI Innovations AB in terms of being a research-university commercialization office offering licensing, incubation, and equity participation in life sciences.
• Cambridge Enterprise (University of Cambridge): Commercialization arm of the University of Cambridge providing technology transfer, seed funding, and incubation for university spinouts, including a strong life sciences portfolio. Same university-affiliated model as KI Innovation.
• Imperial College Innovations: Innovation and commercialization arm of Imperial College London with seed fund, incubator programs, and equity stakes in university spinouts, comparable in scope to KI Innovation but in a different geography.
• BioGenerator: St. Louis-based startup generator/venture capital fund focused exclusively on bioscience startup creation, providing co-investment, lab space, and business support. Comparable to KI Innovation's life science focus and equity participation model.
• ETH Zurich Technology Transfer: Technology transfer office of ETH Zurich supporting spinouts with deep STEM research, including in life sciences and biotech. Closely analogous as a European research university commercialization function.

Broad incumbents

• Johnson & Johnson Innovation (JLABS): Global pharma-operated life science incubator network providing residency, mentoring, and capital to early-stage biotech/healthcare startups. Overlaps with KI Innovation in life science incubation but operates at much larger scale and with corporate capital.

Emerging players

• IndieBio (SOSV): Biotech accelerator providing seed funding, lab space, and mentorship to life science startups. Comparable as an early-stage life science accelerator but operates as an independent VC rather than a university affiliate.
• Startupbootcamp Digital Health: Global accelerator with a Digital Health program providing mentorship and funding to early-stage health startups. Comparable as a life science/healthtech-focused accelerator and connector of capital and founders.

Regional players

• MaRS Discovery District: Toronto-based innovation hub supporting science and technology companies including a substantial life science/healthcare portfolio, with incubator and accelerator functions similar to KI Innovation's Science Park and Incubator.

Others

• Karolinska Institutet Science Park: The KI Science Park itself is operated by KI Innovation; included as an internal reference for the community/incubator platform that is a core distribution channel.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/KIInnovationsAB
• LinkedInlinkedin.com/company/karolinska-institutet-holding
• Instagraminstagram.com/kisciencepark

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Karolinska Institutet Holding